Developer docs
API playgroundTry for free, no card

Search company profiles

Q-Med

Full company profile

uuid0023zmd

Namestring
Q-Med
Legal namestring
Galderma
Websiteurl
q-med.com
Company typeenum
Private
Founded yearint
1981
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
medical implants, aesthetic dermatology, hyaluronic acid fillers, injectable aesthetics, medical devices
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Implants
Social media profiles3 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 22 records shown
1Relfydess
Description

Brand in Galderma's dermatology portfolio

galderma.com
+21 more records
Core offering1 text field

Q-Med is a medical device company that develops, manufactures, markets, and sells medical implants, with a primary focus on hyaluronic acid-based injectable products used in aesthetic dermatology. The company's flagship Restylane brand includes dermal fillers for facial volume restoration and Restylane Skinboosters for skin hydration micro-injections, sold to healthcare professionals and aesthetic practitioners worldwide.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Galderma operates as a diversified dermatology company organized around three core business segments: Injectable Aesthetics (botulinum toxins and dermal fillers such as Dysport, Sculptra, Restylane, Alluzience, Azzalure, and Restylane Skinboosters), Dermatological Skincare (consumer-facing brands including Cetaphil, Differin, Benzac, Loceryl, and Alastin), and Therapeutic Dermatology (prescription brands such as Epiduo, Epiduo Forte, Soolantra, Mirvaso, Oracea, Aklief, Nemluvio, Relfydess, TRI-LUMA, Actinica, and Metvix). The portfolio spans over-the-counter, prescription, and aesthetic practitioner channels.

Product and service2 records
1Restylane
CategoryInjectable Aesthetics
Description

Flagship hyaluronic acid dermal filler brand for facial aesthetic treatments, originally developed by Q-Med for facial volume restoration and wrinkle reduction. Now part of the broader Injectable Aesthetics portfolio distributed globally to aesthetic practitioners and dermatologists.

2Restylane Skinboosters
CategoryInjectable Aesthetics
Description

Sub-brand of Restylane focused on skin hydration and quality improvement through micro-injections of hyaluronic acid, designed for aesthetic practitioners treating patients seeking skin quality enhancement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Croma-Pharma
TypeDirect peer
Description

Croma-Pharma is an Austrian aesthetic medicine specialist offering HA fillers and PRP systems, directly competing with Q-Med in clinics across Europe and Asia-Pacific.

2Teoxane
TypeDirect peer
Description

Teoxane is a Swiss-based HA filler manufacturer (Teosyal range) directly competing with Restylane in the premium dermal filler segment across European and international markets.

3Suneva Medical
TypeEmerging player
Description

Suneva Medical markets Bellafill (PMMA-based filler) and other aesthetics products, operating in the same injectable aesthetics space as Q-Med with an alternative technology platform.

4Evolus
TypeEmerging player
Description

Evolus markets Jeuveau (prabotulinumtoxinA), an aesthetic neurotoxin competing with Galderma's Dysport/Alluzience/Azzalure and broadly adjacent to Q-Med's injectable aesthetics business.

5Hugel
TypeDirect peer
Description

Hugel is a Korean manufacturer offering Botulax/Letybo (botulinum toxin) and HA fillers, directly competing with Q-Med's Restylane and Dysport franchises, particularly in Asia-Pacific markets.

6Allergan Aesthetics (AbbVie)
TypeDirect peer
Description

Allergan Aesthetics, integrated into AbbVie after the 2020 Allergan acquisition, is the global leader in injectable aesthetics with Juvederm (HA fillers) and Botox (botulinum toxin). It is the most direct competitor to Q-Med's Restylane franchise in the HA filler category.

7Revance Therapeutics
TypeDirect peer
Description

Revance Therapeutics developed Daxxify (daxxibotulinumtoxinA), a long-duration neurotoxin competing in the same injectable aesthetics category as Galderma's Dysport and adjacent to Q-Med's HA filler franchise.

8Merz Aesthetics
TypeDirect peer
Description

Merz Aesthetics markets Belotero (HA filler) and Radiesse (calcium hydroxylapatite), directly competing with Q-Med's Restylane in the dermal filler category across dermatology and plastic surgery channels worldwide.

9Prollenium Medical Technologies
TypeEmerging player
Description

Prollenium is a Canadian HA filler manufacturer (Revanesse line) competing with Restylane in the value and mid-tier dermal filler segment across North America and internationally.

10Sinclair Pharma
TypeDirect peer
Description

Sinclair Pharma (now under Huadong Medicine ownership) markets MaiLi and other HA-based injectable aesthetics, directly competing with Q-Med's premium filler franchise in European and select global markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Q-Med

Medical Implantsq-med.com

Q-Med firmographics

Firmographics
Name
Q-Med
Legal name
Galderma
Website
https://q-med.com
Company type
Private
Founded year
1981
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

Where Q-Med is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Markets served

Q-Med business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Q-Med product offering

Product offering

Core offering

Q-Med is a medical device company that develops, manufactures, markets, and sells medical implants, with a primary focus on hyaluronic acid-based injectable products used in aesthetic dermatology. The company's flagship Restylane brand includes dermal fillers for facial volume restoration and Restylane Skinboosters for skin hydration micro-injections, sold to healthcare professionals and aesthetic practitioners worldwide.

Product overview

Galderma operates as a diversified dermatology company organized around three core business segments: Injectable Aesthetics (botulinum toxins and dermal fillers such as Dysport, Sculptra, Restylane, Alluzience, Azzalure, and Restylane Skinboosters), Dermatological Skincare (consumer-facing brands including Cetaphil, Differin, Benzac, Loceryl, and Alastin), and Therapeutic Dermatology (prescription brands such as Epiduo, Epiduo Forte, Soolantra, Mirvaso, Oracea, Aklief, Nemluvio, Relfydess, TRI-LUMA, Actinica, and Metvix). The portfolio spans over-the-counter, prescription, and aesthetic practitioner channels.

Differentiator

Problem solved

Functional benefit

Brands

  • Relfydess: Brand in Galderma's dermatology portfolio
  • Nemluvio
  • TRI-LUMA
  • Actinica
  • Aklief
  • ALASTIN
  • Alluzience
  • Dysport
  • Sculptra
  • Restylane Skinboosters
  • Differin
  • Metvix
  • Epiduo Forte
  • Soolantra
  • Mirvaso
  • Oracea
  • Epiduo
  • Benzac
  • Cetaphil
  • Azzalure
  • Restylane
  • Loceryl

Products and services

  • Restylane Flagship hyaluronic acid dermal filler brand for facial aesthetic treatments, originally developed by Q-Med for facial volume restoration and wrinkle reduction. Now part of the broader Injectable Aesthetics portfolio distributed globally to aesthetic practitioners and dermatologists.
  • Restylane Skinboosters Sub-brand of Restylane focused on skin hydration and quality improvement through micro-injections of hyaluronic acid, designed for aesthetic practitioners treating patients seeking skin quality enhancement.

Companies that use Q-Med

Customer profile

Segments1 record

Ideal customer profiles1 record

Q-Med technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Q-Med partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Q-Med competitors and assessment

Company assessment

Direct peers

  • Croma-Pharma: Croma-Pharma is an Austrian aesthetic medicine specialist offering HA fillers and PRP systems, directly competing with Q-Med in clinics across Europe and Asia-Pacific.
  • Teoxane: Teoxane is a Swiss-based HA filler manufacturer (Teosyal range) directly competing with Restylane in the premium dermal filler segment across European and international markets.
  • Hugel: Hugel is a Korean manufacturer offering Botulax/Letybo (botulinum toxin) and HA fillers, directly competing with Q-Med's Restylane and Dysport franchises, particularly in Asia-Pacific markets.
  • Allergan Aesthetics (AbbVie): Allergan Aesthetics, integrated into AbbVie after the 2020 Allergan acquisition, is the global leader in injectable aesthetics with Juvederm (HA fillers) and Botox (botulinum toxin). It is the most direct competitor to Q-Med's Restylane franchise in the HA filler category.
  • Revance Therapeutics: Revance Therapeutics developed Daxxify (daxxibotulinumtoxinA), a long-duration neurotoxin competing in the same injectable aesthetics category as Galderma's Dysport and adjacent to Q-Med's HA filler franchise.
  • Merz Aesthetics: Merz Aesthetics markets Belotero (HA filler) and Radiesse (calcium hydroxylapatite), directly competing with Q-Med's Restylane in the dermal filler category across dermatology and plastic surgery channels worldwide.
  • Sinclair Pharma: Sinclair Pharma (now under Huadong Medicine ownership) markets MaiLi and other HA-based injectable aesthetics, directly competing with Q-Med's premium filler franchise in European and select global markets.

Emerging players

  • Suneva Medical: Suneva Medical markets Bellafill (PMMA-based filler) and other aesthetics products, operating in the same injectable aesthetics space as Q-Med with an alternative technology platform.
  • Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), an aesthetic neurotoxin competing with Galderma's Dysport/Alluzience/Azzalure and broadly adjacent to Q-Med's injectable aesthetics business.
  • Prollenium Medical Technologies: Prollenium is a Canadian HA filler manufacturer (Revanesse line) competing with Restylane in the value and mid-tier dermal filler segment across North America and internationally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Q-Med social profiles

Digital presence

Q-Med financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Q-Med leadership team

Management profile

Number of profiles

Profiles1 record

Q-Med funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Q-Med M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q-Med

What does Q-Med do?

Q-Med is a medical device company that develops, manufactures, markets, and sells medical implants, with a primary focus on hyaluronic acid-based injectable products used in aesthetic dermatology. The company's flagship Restylane brand includes dermal fillers for facial volume restoration and Restylane Skinboosters for skin hydration micro-injections, sold to healthcare professionals and aesthetic practitioners worldwide.

Is Q-Med a public or private company?

Q-Med is a private company. It is classified as corporate owned and is currently operating.

When was Q-Med founded?

Q-Med was founded in 1981. It employs 5,001 to 10,000 people.

Where is Q-Med based?

Q-Med is headquartered in Uppsala, Sweden, in the Europe region.

Who are Q-Med's main competitors?

Direct peers on record are Croma-Pharma, Teoxane, Hugel, Allergan Aesthetics (AbbVie), Revance Therapeutics, Merz Aesthetics and Sinclair Pharma. Emerging players are Suneva Medical, Evolus and Prollenium Medical Technologies.

Does Q-Med have an API?

No public API is recorded for Q-Med.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDerivatives: Anticipated adjustment in Q-Med due to offer (11/11)Galderma Holding AB announced a public takeover offer for Q-Med shareholders, revised on February 10, 2011, to pay SEK 79 per share. The last trading date is March 25, 2011, and derivatives contracts expire March 22, 2011, settling at fair value.GlobeNewswireDerivatives: Anticipated adjustment in Q-Med due to offer (10/11)Galderma's revised takeover offer for Q-Med pays SEK 79.00 per share, with the last trading date set for March 25, 2011. NASDAQ OMX Derivatives Markets will adjust Q-Med options and forward contracts to expire March 22, 2011, or earlier if trading is insufficient, and settle at fair value.GlobeNewswireQ-Med AB invites to Q3 conference callQ-Med AB will publish its interim report for January-September 2010 on October 22 and host a conference call with CEO Maria Carell and CFO Alexander Kotsinas. The call is at 10:30 am CET, with dial-in numbers and a recorded presentation available.GlobeNewswireAnnual General Meeting of Q-Med AB (publ)Q-Med AB's annual general meeting on April 29, 2009 adopted resolutions to pay no dividend, re-elect the board, and set board fees of 1.4 million SEK for 2009/2010. The meeting also approved a change to shareholder meeting notice procedures and established an election committee.GlobeNewswireQ-Med AB invites to conference call regarding Interim report January-March, 2009Q-Med AB invited investors to a conference call on April 28, 2009, at 10:15 a.m. CET to discuss its Q1 interim report. The press release and slide presentation were to be released at 08:00 a.m. on that date, with a recorded version available for seven working days.GlobeNewswireQ-Med has obtained registration approval for Restylane® in ChinaQ-Med obtained registration approval for Restylane in China, with sales approval application submitted and sales expected to begin in the second quarter of 2009. The product will be the first hyaluronic acid product intended for the cosmetic market in China.GlobeNewswireIndependent Board Committee of Q-Med recommends shareholders not to accept the cash offer from IvytanIvytan, controlled by EQT V and Lyftet Holding, offered SEK 39 per share for Q-Med AB, with acceptance ending December 8, 2008. Q-Med's independent board committee unanimously recommended shareholders reject the offer, citing it as too low and not reflecting long-term potential. Morgan Stanley issued an inadequacy opinion.GlobeNewswireAnnual General Meeting of Q-Med AB (publ)Q-Med AB's annual general meeting on April 29, 2008 approved a dividend of 1.50 SEK per share and re-elected its board members. Board fees for 2007/2008 were set at 1.4 million SEK, with the election committee continuing as three members. The meeting also adopted principles for senior management remuneration.GlobeNewswireQ-Med Interim Report January -- September 2005Q-Med reported interim results for January-September 2005, with turnover of SEK 669.1 million, up 14% year-on-year. Operating income was SEK 59.0 million, and net income after tax was SEK 46.8 million. The company's Hospital Healthcare products grew 53%, and Latin America reorganization is complete.GlobeNewswireQ-Med -- New One-Year Study Gives Hope to Stress Urinary Incontinence SufferersA one-year study of 142 women with stress urinary incontinence treated with ZUIDEX showed 77% response and a median 93% reduction in leakage. The study, presented at the International Continence Society's congress in Paris, found the treatment cost-effective compared to TVT. A long-term follow-up is planned.